KR20080079250A - 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도 - Google Patents
신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도 Download PDFInfo
- Publication number
- KR20080079250A KR20080079250A KR1020087013706A KR20087013706A KR20080079250A KR 20080079250 A KR20080079250 A KR 20080079250A KR 1020087013706 A KR1020087013706 A KR 1020087013706A KR 20087013706 A KR20087013706 A KR 20087013706A KR 20080079250 A KR20080079250 A KR 20080079250A
- Authority
- KR
- South Korea
- Prior art keywords
- bicyclo
- diaza
- nonane
- methyl
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003118 aryl group Chemical group 0.000 title claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 83
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 208000035475 disorder Diseases 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 208000002193 Pain Diseases 0.000 claims abstract description 21
- 230000001713 cholinergic effect Effects 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 14
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 7
- -1 selenophenyl Chemical group 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000001544 thienyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 13
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 12
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 12
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims description 11
- 229960002715 nicotine Drugs 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- 125000001041 indolyl group Chemical group 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 125000004306 triazinyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 229940049706 benzodiazepine Drugs 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- XSQQPNAJQNHRDG-UHFFFAOYSA-N 3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1C(N2)CCCC2CN1C(N=N1)=CC=C1C1=CC=CC=C1 XSQQPNAJQNHRDG-UHFFFAOYSA-N 0.000 claims description 4
- VUWLIVJBMFYYTA-UHFFFAOYSA-N 3-[5-(1-benzofuran-2-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2OC(C3=CN=C(N=C3)N3CC4CCCC(C3)N4C)=CC2=C1 VUWLIVJBMFYYTA-UHFFFAOYSA-N 0.000 claims description 4
- KEMGSELFJOETLU-UHFFFAOYSA-N 3-[5-(1h-indol-5-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)N2CC3CCCC(C2)N3C)=C1 KEMGSELFJOETLU-UHFFFAOYSA-N 0.000 claims description 4
- RMBARHWXTKPXTF-UHFFFAOYSA-N 3-[6-(1-benzofuran-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2OC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC2=C1 RMBARHWXTKPXTF-UHFFFAOYSA-N 0.000 claims description 4
- VZYSWDFEPJQXTQ-UHFFFAOYSA-N 3-[6-(1-benzothiophen-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2SC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC2=C1 VZYSWDFEPJQXTQ-UHFFFAOYSA-N 0.000 claims description 4
- KKYYDKUWGOVCGA-UHFFFAOYSA-N 3-[6-(2,3-difluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1F KKYYDKUWGOVCGA-UHFFFAOYSA-N 0.000 claims description 4
- YZFUYFPDFPMBDN-UHFFFAOYSA-N 3-[6-(2,3-dimethoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCCC(N3C)C2)=C1OC YZFUYFPDFPMBDN-UHFFFAOYSA-N 0.000 claims description 4
- OJZHWYNIPYNESI-UHFFFAOYSA-N 3-[6-(3,4-difluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C(F)=C1 OJZHWYNIPYNESI-UHFFFAOYSA-N 0.000 claims description 4
- IOENKEPDMCPFPM-UHFFFAOYSA-N 3-[6-(3,4-dimethoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 IOENKEPDMCPFPM-UHFFFAOYSA-N 0.000 claims description 4
- JRHLBFCRXCSEPV-UHFFFAOYSA-N 9-methyl-3-(5-naphthalen-2-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=CC2=CC(C3=CN=C(N=C3)N3CC4CCCC(C3)N4C)=CC=C21 JRHLBFCRXCSEPV-UHFFFAOYSA-N 0.000 claims description 4
- GAJASBATEWQDPZ-UHFFFAOYSA-N 9-methyl-3-(5-phenylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CC=C1 GAJASBATEWQDPZ-UHFFFAOYSA-N 0.000 claims description 4
- STSJVLWHJVKQCN-UHFFFAOYSA-N 9-methyl-3-(6-naphthalen-2-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=CC2=CC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC=C21 STSJVLWHJVKQCN-UHFFFAOYSA-N 0.000 claims description 4
- GQYYKRWORSNPBS-UHFFFAOYSA-N 9-methyl-3-[6-[3-(trifluoromethyl)phenyl]pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 GQYYKRWORSNPBS-UHFFFAOYSA-N 0.000 claims description 4
- ZSLOGSYNSRFQFQ-UHFFFAOYSA-N 9-methyl-3-[6-[4-(trifluoromethyl)phenyl]pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 ZSLOGSYNSRFQFQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- JXUDAISOBGNDHQ-UHFFFAOYSA-N 3-[6-(2-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1F JXUDAISOBGNDHQ-UHFFFAOYSA-N 0.000 claims description 3
- VEWDKPOTHCJJCR-UHFFFAOYSA-N 9-ethyl-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CCN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 VEWDKPOTHCJJCR-UHFFFAOYSA-N 0.000 claims description 3
- YBVCONMKJCCKQC-UHFFFAOYSA-N 9-methyl-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 YBVCONMKJCCKQC-UHFFFAOYSA-N 0.000 claims description 3
- NCKJDGFAVZUBPM-UHFFFAOYSA-N 9-methyl-3-[6-(1h-pyrrol-2-yl)pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CN1 NCKJDGFAVZUBPM-UHFFFAOYSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 229960002069 diamorphine Drugs 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 206010013932 dyslexia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- FGOQONPFPVZWHX-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)-1,3,4-thiadiazole Chemical compound CN1C(C2)CCCC1CN2C(S1)=NN=C1C1=CC=C(Cl)C=C1 FGOQONPFPVZWHX-UHFFFAOYSA-N 0.000 claims description 2
- IDISALVIHFLVGH-UHFFFAOYSA-N 2-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)-5-phenyl-1,3,4-thiadiazole Chemical compound CN1C(C2)CCCC1CN2C(S1)=NN=C1C1=CC=CC=C1 IDISALVIHFLVGH-UHFFFAOYSA-N 0.000 claims description 2
- CYNAMJOAZBZKAX-UHFFFAOYSA-N 3-(6-phenylpyridazin-3-yl)-9-propan-2-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CC(C)N1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 CYNAMJOAZBZKAX-UHFFFAOYSA-N 0.000 claims description 2
- IKRUSLRJFTUYHB-UHFFFAOYSA-N 3-[5-(furan-2-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CO1 IKRUSLRJFTUYHB-UHFFFAOYSA-N 0.000 claims description 2
- DHFHVVFDTGXXGW-UHFFFAOYSA-N 3-[5-(furan-3-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=COC=1 DHFHVVFDTGXXGW-UHFFFAOYSA-N 0.000 claims description 2
- PUYRDTPXVOXEAZ-UHFFFAOYSA-N 3-[6-(1,3-benzodioxol-5-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2OCOC2=CC(C2=CC=C(N=N2)N2CC3CCCC(C2)N3C)=C1 PUYRDTPXVOXEAZ-UHFFFAOYSA-N 0.000 claims description 2
- XSGLPUSPWSLWGK-UHFFFAOYSA-N 3-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound O1CCOC2=CC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC=C21 XSGLPUSPWSLWGK-UHFFFAOYSA-N 0.000 claims description 2
- XFXGDPHXKMDYST-UHFFFAOYSA-N 3-[6-(2-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 XFXGDPHXKMDYST-UHFFFAOYSA-N 0.000 claims description 2
- BIOCLXADHCTJJA-UHFFFAOYSA-N 3-[6-(3-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(Cl)=C1 BIOCLXADHCTJJA-UHFFFAOYSA-N 0.000 claims description 2
- SHZQLOVONNAGPP-UHFFFAOYSA-N 3-[6-(3-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1 SHZQLOVONNAGPP-UHFFFAOYSA-N 0.000 claims description 2
- PYOUOBGQJNWMCN-UHFFFAOYSA-N 3-[6-(3-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCCC(N3C)C2)=C1 PYOUOBGQJNWMCN-UHFFFAOYSA-N 0.000 claims description 2
- ODYJYCSNOBKQJA-UHFFFAOYSA-N 3-[6-(4-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)C=C1 ODYJYCSNOBKQJA-UHFFFAOYSA-N 0.000 claims description 2
- IJEACVLCQBWHBA-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C=C1 IJEACVLCQBWHBA-UHFFFAOYSA-N 0.000 claims description 2
- UFPXNUQARADVFM-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 UFPXNUQARADVFM-UHFFFAOYSA-N 0.000 claims description 2
- KVDZBHUCZJIWTJ-UHFFFAOYSA-N 3-[6-(5-chlorothiophen-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)S1 KVDZBHUCZJIWTJ-UHFFFAOYSA-N 0.000 claims description 2
- VZOUJCBJYJVQBQ-UHFFFAOYSA-N 3-[6-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)pyridazin-3-yl]aniline Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(N)=C1 VZOUJCBJYJVQBQ-UHFFFAOYSA-N 0.000 claims description 2
- QNFKEPYFXNMHBG-UHFFFAOYSA-N 3-[6-(furan-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CO1 QNFKEPYFXNMHBG-UHFFFAOYSA-N 0.000 claims description 2
- IQHDJOUFKKIVFV-UHFFFAOYSA-N 3-[6-(furan-3-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=COC=1 IQHDJOUFKKIVFV-UHFFFAOYSA-N 0.000 claims description 2
- JFWZGJMWQOKJMP-UHFFFAOYSA-N 9-(2-methoxyethyl)-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound COCCN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 JFWZGJMWQOKJMP-UHFFFAOYSA-N 0.000 claims description 2
- UTXORWNBSQBQHP-UHFFFAOYSA-N 9-methyl-3-(5-thiophen-2-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CS1 UTXORWNBSQBQHP-UHFFFAOYSA-N 0.000 claims description 2
- GPYXLWLDRHEQQL-UHFFFAOYSA-N 9-methyl-3-(5-thiophen-3-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=CSC=1 GPYXLWLDRHEQQL-UHFFFAOYSA-N 0.000 claims description 2
- KYCGHQNQAAJCII-UHFFFAOYSA-N 9-methyl-3-(6-thiophen-2-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CS1 KYCGHQNQAAJCII-UHFFFAOYSA-N 0.000 claims description 2
- FGMNOBQFMPYCPT-UHFFFAOYSA-N 9-methyl-3-(6-thiophen-3-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=CSC=1 FGMNOBQFMPYCPT-UHFFFAOYSA-N 0.000 claims description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 230000029849 luteinization Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 14
- 108020003175 receptors Proteins 0.000 abstract description 14
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract description 9
- 102000034337 acetylcholine receptors Human genes 0.000 abstract description 9
- 210000003169 central nervous system Anatomy 0.000 abstract description 9
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 abstract description 7
- 210000001428 peripheral nervous system Anatomy 0.000 abstract description 7
- 230000016160 smooth muscle contraction Effects 0.000 abstract description 6
- 208000017701 Endocrine disease Diseases 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 208000030172 endocrine system disease Diseases 0.000 abstract description 3
- 239000003446 ligand Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 17
- 239000012458 free base Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- ITAIMJJXAZZCQW-UHFFFAOYSA-N 3-(5-bromopyrimidin-2-yl)-9-methyl-9-azabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CC2C1=NC=C(Br)C=N1 ITAIMJJXAZZCQW-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000001530 fumaric acid Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- NHNRLASXGHTJKZ-UHFFFAOYSA-N 9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1CCC2CNCC1N2C NHNRLASXGHTJKZ-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 3
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- OQMLCRBPKABPBT-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-(6-phenylpyridazin-3-yl)-9-propan-2-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CC(C)N1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 OQMLCRBPKABPBT-WLHGVMLRSA-N 0.000 description 2
- ZATLFIIMLBPXRY-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[5-(furan-2-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CO1 ZATLFIIMLBPXRY-WLHGVMLRSA-N 0.000 description 2
- YXAAFRYZJRBHLY-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[5-(furan-3-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=COC=1 YXAAFRYZJRBHLY-WLHGVMLRSA-N 0.000 description 2
- JWEPOJCBLDDMFL-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.O1CCOC2=CC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC=C21 JWEPOJCBLDDMFL-WLHGVMLRSA-N 0.000 description 2
- UHORMPCYFFCFIT-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(3-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(Cl)=C1 UHORMPCYFFCFIT-WLHGVMLRSA-N 0.000 description 2
- LSTHCLUVMGEWQU-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(3-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1 LSTHCLUVMGEWQU-WLHGVMLRSA-N 0.000 description 2
- VDHCLUUENNWGRY-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(3-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCCC(N3C)C2)=C1 VDHCLUUENNWGRY-WLHGVMLRSA-N 0.000 description 2
- IIOAARNSRCPFSW-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(4-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)C=C1 IIOAARNSRCPFSW-WLHGVMLRSA-N 0.000 description 2
- LHJTXCVWTLJQQW-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)pyridazin-3-yl]aniline Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(N)=C1 LHJTXCVWTLJQQW-WLHGVMLRSA-N 0.000 description 2
- KFYNDMVZDVJZPK-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(furan-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CO1 KFYNDMVZDVJZPK-WLHGVMLRSA-N 0.000 description 2
- KUWNFFPACREXGA-WLHGVMLRSA-N (E)-but-2-enedioic acid 9-(2-methoxyethyl)-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.COCCN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 KUWNFFPACREXGA-WLHGVMLRSA-N 0.000 description 2
- MJESSZZKSPALGN-WLHGVMLRSA-N (E)-but-2-enedioic acid 9-methyl-3-(5-thiophen-2-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CS1 MJESSZZKSPALGN-WLHGVMLRSA-N 0.000 description 2
- OYHHQIBNFICUBO-WLHGVMLRSA-N (E)-but-2-enedioic acid 9-methyl-3-(6-thiophen-3-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=CSC=1 OYHHQIBNFICUBO-WLHGVMLRSA-N 0.000 description 2
- XONJJOVUWILBSV-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-[6-(1h-indol-5-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.C1=C2NC=CC2=CC(C2=CC=C(N=N2)N2CC3CCCC(C2)N3C)=C1 XONJJOVUWILBSV-WLHGVMLRSA-N 0.000 description 2
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VYBRBZPMUOLVIN-UHFFFAOYSA-N 3-(6-iodopyridazin-3-yl)-9-methyl-9-azabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CC2C1=CC=C(I)N=N1 VYBRBZPMUOLVIN-UHFFFAOYSA-N 0.000 description 2
- BUBRFWDEAVIFMV-UHFFFAOYSA-N 3-chloro-6-phenylpyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=CC=C1 BUBRFWDEAVIFMV-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- RGSICJUTWGMYOY-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=CSC=1 Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=CSC=1 RGSICJUTWGMYOY-WLHGVMLRSA-N 0.000 description 2
- MPNPKNFQABGTNG-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C=C1 Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C=C1 MPNPKNFQABGTNG-WLHGVMLRSA-N 0.000 description 2
- SOLACRXHUJRNES-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 SOLACRXHUJRNES-WLHGVMLRSA-N 0.000 description 2
- MYOLIYVZVZTTNQ-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=COC=1 Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=COC=1 MYOLIYVZVZTTNQ-WLHGVMLRSA-N 0.000 description 2
- XBJZKQQFYCBVBU-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.COC1=CC=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 Chemical compound OC(=O)\C=C\C(O)=O.COC1=CC=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 XBJZKQQFYCBVBU-WLHGVMLRSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 201000009863 inflammatory diarrhea Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WITGKWXUOUZWFA-WLHGVMLRSA-N (E)-but-2-enedioic acid 2-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)-5-phenyl-1,3,4-thiadiazole Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(S1)=NN=C1C1=CC=CC=C1 WITGKWXUOUZWFA-WLHGVMLRSA-N 0.000 description 1
- AIODSGDZQLHNAY-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[6-(4-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 AIODSGDZQLHNAY-WLHGVMLRSA-N 0.000 description 1
- WAFLVNFXWBKNIN-WLHGVMLRSA-N (E)-but-2-enedioic acid 9-methyl-3-(6-thiophen-2-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CS1 WAFLVNFXWBKNIN-WLHGVMLRSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- ZSPTWYFBSHTTGE-UHFFFAOYSA-N 2-chloro-5-(4-chlorophenyl)-1,3,4-oxadiazole Chemical compound O1C(Cl)=NN=C1C1=CC=C(Cl)C=C1 ZSPTWYFBSHTTGE-UHFFFAOYSA-N 0.000 description 1
- QSGNNXKJPIMRPO-UHFFFAOYSA-N 2-chloro-5-phenyl-1,3,4-oxadiazole Chemical compound O1C(Cl)=NN=C1C1=CC=CC=C1 QSGNNXKJPIMRPO-UHFFFAOYSA-N 0.000 description 1
- GCLHXKPPHRIJOE-UHFFFAOYSA-N 3,6-diiodopyridazine Chemical compound IC1=CC=C(I)N=N1 GCLHXKPPHRIJOE-UHFFFAOYSA-N 0.000 description 1
- PJDJTXWCVQUXKZ-UHFFFAOYSA-N 3,9-diazabicyclo[3.3.1]nonane Chemical compound C1NCC2CCCC1N2 PJDJTXWCVQUXKZ-UHFFFAOYSA-N 0.000 description 1
- OHRXMAVNLQVSHQ-UHFFFAOYSA-N 3-[6-(1h-indol-5-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)N2CC3CCCC(C2)N3C)=C1 OHRXMAVNLQVSHQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IQAGDEVIPVREPI-UHFFFAOYSA-N 3-benzyl-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2CC1=CC=CC=C1 IQAGDEVIPVREPI-UHFFFAOYSA-N 0.000 description 1
- YRBWBBYDWXPXMM-UHFFFAOYSA-N 3-benzyl-9-methyl-3,9-diazabicyclo[3.3.1]nonane-2,4-dione Chemical compound CN1C(C2=O)CCCC1C(=O)N2CC1=CC=CC=C1 YRBWBBYDWXPXMM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 241000272079 Bungarus multicinctus Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- XZPLFFKVAZVTLV-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)S1 Chemical compound OC(=O)\C=C\C(O)=O.CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)S1 XZPLFFKVAZVTLV-WLHGVMLRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- ZIQCCIAIROIHHR-UHFFFAOYSA-N benzene;boric acid Chemical compound OB(O)O.C1=CC=CC=C1 ZIQCCIAIROIHHR-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- GGNALUCSASGNCK-UHFFFAOYSA-N carbon dioxide;propan-2-ol Chemical compound O=C=O.CC(C)O GGNALUCSASGNCK-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical group F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ISWNAMNOYHCTSB-UHFFFAOYSA-N methanamine;hydrobromide Chemical compound [Br-].[NH3+]C ISWNAMNOYHCTSB-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- IYEIBEGTNKJTKQ-UHFFFAOYSA-N methylsulfonyloxymethanesulfonic acid Chemical compound CS(=O)(=O)OCS(O)(=O)=O IYEIBEGTNKJTKQ-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- IZLGOGRHBJIRNU-UHFFFAOYSA-N tert-butyl 3,9-diazabicyclo[3.3.1]nonane-9-carboxylate Chemical compound C1CCC2CNCC1N2C(=O)OC(C)(C)C IZLGOGRHBJIRNU-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501724 | 2005-12-06 | ||
| DKPA200501724 | 2005-12-06 | ||
| US74822205P | 2005-12-08 | 2005-12-08 | |
| US60/748,222 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080079250A true KR20080079250A (ko) | 2008-08-29 |
Family
ID=40114330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087013706A Withdrawn KR20080079250A (ko) | 2005-12-06 | 2006-12-05 | 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8173658B2 (enExample) |
| EP (2) | EP1963323B1 (enExample) |
| JP (1) | JP2009518357A (enExample) |
| KR (1) | KR20080079250A (enExample) |
| CN (1) | CN101305004B (enExample) |
| AT (1) | ATE473978T1 (enExample) |
| AU (1) | AU2006323986A1 (enExample) |
| BR (1) | BRPI0617772A2 (enExample) |
| CA (1) | CA2632642A1 (enExample) |
| DE (1) | DE602006015523D1 (enExample) |
| DK (1) | DK1963323T3 (enExample) |
| NZ (1) | NZ567048A (enExample) |
| RU (1) | RU2008110911A (enExample) |
| WO (1) | WO2007065892A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009526024A (ja) | 2006-02-10 | 2009-07-16 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体アゴニストとしての３−ヘテロアリール−３，９−ジアザビシクロ［３．３．１］ノナン誘導体 |
| CA2641683A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7700596B2 (en) | 2006-02-10 | 2010-04-20 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7855208B2 (en) | 2006-02-14 | 2010-12-21 | Neurosearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
| US7910578B2 (en) | 2006-05-23 | 2011-03-22 | Neurosearch A/S | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| EP2288609A2 (en) * | 2008-06-10 | 2011-03-02 | NeuroSearch A/S | Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| BR122014023207A2 (pt) | 2010-09-23 | 2019-05-28 | Abbvie Inc. | Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN108658762B (zh) * | 2018-06-12 | 2021-03-02 | 浙江凯普化工有限公司 | 一种脂环邻二酯的合成方法 |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3293251A (en) * | 1966-12-20 | Rearrangement process for j,b-diaza- bicyclo-(j,z,i)-octane derivatives | ||
| US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| TR199902942T2 (xx) | 1997-05-30 | 2000-04-21 | Neurosearch A/S | Nikotinik ACh Resept�rlerinde kolinerjik ligandlar olarak 8-Azabisiklo(3.2.1)okt-ene ve okstan t�revleri. |
| JP2002502383A (ja) * | 1997-05-30 | 2002-01-22 | ニューロサーアチ・アクティーゼルスカブ | ニコチンＡＣｈレセプターに於けるコリン作動性リガンドとしての９−アザビシクロ（３．３．１）ノン−２−エン及びノナン誘導体 |
| FR2786770B1 (fr) | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| US7265115B2 (en) * | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| CN1345320A (zh) | 1999-01-29 | 2002-04-17 | 艾博特公司 | 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物 |
| DE60008866T2 (de) | 1999-05-04 | 2005-01-27 | Neurosearch A/S | Heteroaryl diazabicycloalkene, deren herstellung und verwendung |
| JP2003534344A (ja) | 2000-05-25 | 2003-11-18 | ターガセプト，インコーポレイテッド | ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン |
| FR2809731B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
| FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| WO2002002564A1 (en) | 2000-07-04 | 2002-01-10 | Neurosearch A/S | Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| DE60203007T2 (de) * | 2001-06-01 | 2005-07-07 | Neurosearch A/S | Heteroaryl-diazabicycloalkanderivaten als cns-modulatoren |
| FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| FR2832712B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique |
| DK1506200T3 (da) * | 2002-05-07 | 2007-04-10 | Neurosearch As | Diazabicykliske biarylderivater |
| ATE345342T1 (de) | 2002-11-11 | 2006-12-15 | Neurosearch As | 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| NZ553622A (en) | 2004-10-20 | 2010-08-27 | Neurosearch As | Novel diazabicyclic aryl derivatives and their medical use |
| MX2007003331A (es) | 2004-11-30 | 2007-06-05 | Neurosearch As | Nuevos derivados de arilo diazabiciclico. |
| WO2006087306A2 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors |
| JP5052952B2 (ja) * | 2007-05-07 | 2012-10-17 | 東芝機械株式会社 | マイクロレンズ転写成形用ロールの製造方法および製造装置 |
| AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
-
2006
- 2006-12-05 EP EP06830366A patent/EP1963323B1/en not_active Not-in-force
- 2006-12-05 WO PCT/EP2006/069316 patent/WO2007065892A1/en not_active Ceased
- 2006-12-05 DK DK06830366.8T patent/DK1963323T3/da active
- 2006-12-05 AT AT06830366T patent/ATE473978T1/de active
- 2006-12-05 BR BRPI0617772-7A patent/BRPI0617772A2/pt not_active IP Right Cessation
- 2006-12-05 EP EP10164285A patent/EP2246352A1/en not_active Withdrawn
- 2006-12-05 CA CA002632642A patent/CA2632642A1/en not_active Abandoned
- 2006-12-05 NZ NZ567048A patent/NZ567048A/en not_active IP Right Cessation
- 2006-12-05 CN CN2006800416608A patent/CN101305004B/zh not_active Expired - Fee Related
- 2006-12-05 AU AU2006323986A patent/AU2006323986A1/en not_active Abandoned
- 2006-12-05 KR KR1020087013706A patent/KR20080079250A/ko not_active Withdrawn
- 2006-12-05 DE DE602006015523T patent/DE602006015523D1/de active Active
- 2006-12-05 US US12/093,655 patent/US8173658B2/en not_active Expired - Fee Related
- 2006-12-05 RU RU2008110911/04A patent/RU2008110911A/ru unknown
- 2006-12-05 JP JP2008543818A patent/JP2009518357A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1963323T3 (da) | 2010-10-25 |
| NZ567048A (en) | 2010-12-24 |
| DE602006015523D1 (de) | 2010-08-26 |
| RU2008110911A (ru) | 2010-01-20 |
| CN101305004A (zh) | 2008-11-12 |
| US8173658B2 (en) | 2012-05-08 |
| CA2632642A1 (en) | 2007-06-14 |
| JP2009518357A (ja) | 2009-05-07 |
| ATE473978T1 (de) | 2010-07-15 |
| AU2006323986A1 (en) | 2007-06-14 |
| CN101305004B (zh) | 2011-11-16 |
| EP1963323A1 (en) | 2008-09-03 |
| US20080280912A1 (en) | 2008-11-13 |
| WO2007065892A1 (en) | 2007-06-14 |
| EP1963323B1 (en) | 2010-07-14 |
| BRPI0617772A2 (pt) | 2011-08-09 |
| EP2246352A1 (en) | 2010-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7750011B2 (en) | Diazabicyclic aryl derivatives and their medical use | |
| KR20080079250A (ko) | 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도 | |
| EP1805183B1 (en) | Novel diazabicyclic aryl derivatives and their medical use | |
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| US7678788B2 (en) | Diazabicyclic aryl derivatives | |
| JP2007520527A (ja) | ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体 | |
| JP2008530172A (ja) | ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用 | |
| US7652010B2 (en) | Azabicyclic aryl derivatives and their medical use | |
| US7223753B2 (en) | Diazabicyclic biaryl derivatives | |
| US7612074B2 (en) | Diazabicyclic aryl derivatives as cholinergy ligands | |
| US7662812B2 (en) | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | |
| HK1125929A (en) | Novel diazabicyclic aryl derivatives and their medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080605 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |